Key points from article :
Mayo Clinic, pilot study used dasatinib and quercetin to treat idiopathic pulmonary fibrosis.
Pulmonary fibrosis causes scarring of the lung tissue, leading to loss of function.
When the disease’s origin is unknown, it is called idiopathic pulmonary fibrosis, or IPF.
Combination of dasatinib and quercetin already shown to have beneficial result in mice.
Fourteen patients with IPF were recruited for this pilot study.
Physical function was significantly and clinically-meaningfully improved.
But pulmonary function, clinical chemistries, and frailty index were unchanged.
Next step is to launch a larger-scale study to establish optimal dosage.
Different senolytics appear to favour particular cell and tissue types over others.
The study was published in the EBioMedicine journal.
